BTIG Research reiterated their buy rating on shares of Galapagos NV (NASDAQ:GLPG) in a research report sent to investors on Wednesday morning. BTIG Research currently has a $98.00 price objective on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on GLPG. Zacks Investment Research raised shares of Galapagos NV from a hold rating to a buy rating and set a $86.00 target price on the stock in a research report on Friday, July 14th. Janney Montgomery Scott raised shares of Galapagos NV from a sell rating to a neutral rating in a research report on Friday, July 7th. They noted that the move was a valuation call. Instinet reaffirmed a buy rating and set a $108.00 target price (down previously from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. Nomura dropped their target price on shares of Galapagos NV from $108.00 to $121.00 and set a buy rating on the stock in a research report on Thursday, June 22nd. Finally, Cowen and Company reaffirmed a buy rating on shares of Galapagos NV in a research report on Wednesday, June 21st. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Galapagos NV has an average rating of Buy and an average price target of $93.33.

Shares of Galapagos NV (NASDAQ:GLPG) traded up 0.27% during trading on Wednesday, hitting $80.53. 185,012 shares of the stock were exchanged. Galapagos NV has a 12-month low of $51.91 and a 12-month high of $94.88.

COPYRIGHT VIOLATION WARNING: “Galapagos NV (NASDAQ:GLPG) Stock Rating Reaffirmed by BTIG Research” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/galapagos-nv-nasdaqglpg-stock-rating-reaffirmed-by-btig-research/1462847.html.

A number of large investors have recently made changes to their positions in GLPG. Bogle Investment Management L P DE acquired a new stake in shares of Galapagos NV during the first quarter valued at about $368,000. Airain ltd acquired a new stake in shares of Galapagos NV during the first quarter valued at about $237,000. Wellington Management Group LLP raised its stake in shares of Galapagos NV by 9.5% in the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after buying an additional 39,729 shares during the period. Bank of Montreal Can raised its stake in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares during the period. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Galapagos NV during the first quarter valued at about $942,000. 19.94% of the stock is currently owned by hedge funds and other institutional investors.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.